ArticleCancer management and research2026
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cancer therapy remains challenging because of recurrence, drug resistance, and severe side effects, driving the search for novel complementary strategies. In this study, we explore, for the first time, the potential of Materials and Methods: BT-474 cells were treated with Results: Our findings demonstrate PNEE's multimodal activity in BT-474 cells, decreasing cell viability with an IC Conclusion: PNEE exerts multiple anticancer effects in BT-474 luminal B breast cancer cells and induces a regulated cell death phenotype that does not fully conform to a canonical caspase-dependent apoptotic pattern. Distinct cell death responses observed between BT-474 and MCF-7 cells further suggest that breast cancer subtype-specific factors may influence the cellular response to PNEE. These findings support further investigation of PNEE, including mechanistic studies and evaluation of efficacy and safety in appropriate in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.